in two patients two were used and in five patients three or more were used. The delay in onset of the first clinical features of hepatitis was shortened by increasing the number of drugs combined with sodium valproate and was significantly decreased when the combination was with two or more drugs not considered as enzyme inducing agents (Fig. 4) 
Experimental studies and mechanisms of hepatotoxicity
Experimental studies by us (J M Tredger and H M Smith, unpublished observations) have shown that the administration to mice of large single intraperitoneal doses of sodium valproate (400-1000 mg/kg) can produce a dose dependent microvesicular hepatic steatosis. These observations parallel those obtained in rats by Lewis et al.S3 The same investigators showed that phenobarbitone could augment the fatty infiltration induced by valproic acid given acutely and our findings suggest that this is also true after chronic administration of sodium valproate. In mice and rats the acute administration of sodium valproate alone or after pretreatment with the microsomal enzyme inducing agents phenobarbitone, ,B-naphthoflavone, pregnenolone 16 v-carbonitrile, Arochlor 1254 and clofibrate produced no significant liver necrosis and no increase in serum aspartate aminotransferase activity. Such findings suggest that metabolites of valproate whose production in rodents is augmented by common enzyme inducing agents are not acutely hepatotoxic. This does not, however, preclude the involvement in susceptible human individuals of particular metabolites whose sustained production may lead to liver damage and may be augmented by coprescribed drugs, including those not established as inducing agents.
In man the relatively frequent occurrence of minor reactions, their reversibility on stopping or reducing the dose of valproate together with the occasional, though rare, severe cases suggests a mixed direct hepatotoxicity/idiosyncratic reaction. Similar considerations apply to the hepatotoxicity of other drugs, such as isoniazid.54 5 The lack of rash and eosinophilia distinguishes valproate hepatotoxicity from other drug reactions such as that associated with paraminosalicylic acid,56 where generalised hypersensitivity is thought to be the mechanism. The occurrence of microvesicular fatty infiltration has not been described in immunologically mediated hepatotoxic reactions and is more likely to result from direct interference with mitochondrial function and fatty acid oxidation by valproate or one of its metabolites. The most likely of these is 2-propyl-4-pentenoic acid because structural analogues of this metabolite are known to have hepatotoxic effects similar to valproate. For example, 4-pentenoic acid produces a Reye's-like syndrome in rats58 and methylenecyclopropylacetate, a metabolite of hypoglycin, gives rise to microvesicular hepatic steatosis in Jamaican vomiting sickness.57 58 A different metabolite, however, may be responsible for the development of hepatic necrosis as steatosis and necrosis appear to occur independently of each other after valproate ingestion. It is also possible that the necrosis is sometimes related to other drugs (or their metabolites) administered concurrently with sodium valproate.
With respect to the hyperammonaemia, Coulter and Allen have postulated a role for the valproate metabolite, propionic acid, concentrations of which were increased in four children who experienced severe vomiting, lethargy or coma while on the drug.32 The observed rise in blood ammonia concentrations in one of these children was attributed to inhibition of the urea cycle enzyme, carbamyl phosphate synthetase I by propionate. These proposals, however, are not consistent with observations that propionate did not inhibit urea cycle enzymes in vitro whereas valproate did59 and that increases in blood ammonia concentrations have been noted without concomitant rises in the concentrations of propionic acid. 35 Use of liver function tests in monitoring valproate therapy Measurement of serum aminotransferase will be of most value during the first three months of therapy when the frequency of hepatotoxic reactions is greatest. Such monitoring should be mandatory in the apparently predisposed patients with mental retardation, structural brain damage or metabolic disorders. Particular care should attend multiple drug therapy because this appears to accelerate the onset of valproate hepatotoxicity. Testing at monthly intervals would be a reasonable frequency and in those patients in whom abnormalities of serum aminotransferases develop, the dose of valproate should be lowered until the values return to normal. Failure of normalisation or a continued rise in aminotransferases is an indication for withdrawal of the drug and careful observation of the patient for early symptoms of hepatitis such a lethargy, lassitude, anorexia, nausea, and vomiting. Despite these precautions, it is likely that a small number of severe reactions related to individual idiosyncracy will not be prevented from developing abruptly without preceding rises in serum aminotransferase concentrations.
We are indebted to Labaz, Sanofi, UK Ltd for providing us with data on cases not previously reported in the literature.
